RE:RE:RE:Finally! Easy to parse data!LaserStock29 wrote: riverrrow wrote: Thanks for the post DJDawg. What I really like about the trial data so far is that the 5 patients that were CR at 360 days were still CR at 450 days. Seems like wonderful news for the patients, some peace of mind once they reach 360 days. GLTA.
Any chance of the stock price going back up before agm? Novartis bought Endocyte for 2.1b in 2018 for its radionucleotide. I hope Novartis buys us out to build out their oncology division ... I hope that's what Vera is really here for. I pray we don't do another pp. We need a grant or some non dilutive funding . Not stories of how great our tech is in saving the canadian system with our 50m cap company out of east york. More 2014 talk
The data is already coming in much better Laser. Much easier to convince an Angel investor to buy at market to boost SP. Or, find an extra $ Million ot two in a drawer somewhere. They need to extend the warrants maybe? But only maybe.
Should have news out this Summer on GLP, Covid animal models, and this data will be coming in and improving, so maybe with 21 evaluable already that is enough to go to FDA to apply for BTD a bit early?? I guess it depends on how much the CR %s keep improving. I like what I am seeing soo far...